Expression and mutational status of PDGFR in thymic tumours

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4057-4061

  Meister, Michael ^a   Kahl, Philip ^b   Muley, Thomas ^a   Morresi Hauf, Alicia ^c   Sebening, Christian ^d   Kern, Michael A ^d   Breinig, Marco ^d   Schnabel, Philipp ^d   Dienemann, Hendrik ^a   Schirmacher, Peter ^d   Rieker, Ralf J ^d,e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Asklepios Fachkliniken ^*  (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Mutations; PDGFR; Thymic carcinoma; Thymoma

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMOMA; THYMUS CANCER;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; THYMUS NEOPLASMS;

EID: 71949120153     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Rosai J and Sobin LH (eds.): Histological Typing of Tumors of the Thymus. World Health Organization. International Histological Classification of Tumours. Heidelberg, Germany, Springer Verlag, pp. 9-23, 1999.
2. Travis WD, Brambilla E, Müller-Hermelink HK and Harris CC (eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France, IARC Press, pp. 145-187, 2004.
3. Strobel P, Marx A, Zettl A and Müller-Hermelink HK: Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg Today 35: 805-811, 2005.
4. Rieker RJ, Hoegel J, Morresi-Hauf A, Hofmann WJ, Blaeker H, Penzel R and Otto HF: Histologic classification of thymic epithelial tumors: comparison of established classification schemes. Int J Cancer 98: 900-906, 2002. (Pubitemid 34286688)
5. Gupta R, Marchevsky AM, McKenna RJ, Wick M, Moran C, Zakowski MF and Suster S: Evidence-based pathology and the pathologic evaluation of thymomas: transcapsular invasion is not a significant prognostic feature. Arch Pathol Lab Med 132: 926-930, 2008. (Pubitemid 351918697)
6. Rieker RJ, Muley T, Klein C, Schnabel PA, Herpel E, Meister M, Schirmacher P, Dienemann H and Pfannschmidt J: An institutional study on thymomas and thymic carcinomas: experience in 77 patients. Thorac Cardiovasc Surg 56: 143-147, 2008. (Pubitemid 351547735)
7. Giaccone G: Treatment of malignant thymoma. Curr Opin Oncol 17: 140-146, 2005.
8. Rieker RJ, Joos S, Mechtersheimer G, Blaeker H, Schnabel PA, Morresi-Hauf A, Hecker E, Thomas M, Dienemann H, Schirmacher P and Kern MA: COX-2 up-regulation in thymomas and thymic carcinomas. Int J Cancer 119: 2063-2070, 2006. (Pubitemid 44423662)
9. Kurup A, Burns M, Dropcho S, Pao W and Loehrer PJ: Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 23, No 16S(1 Suppl): 7068, 2005.
10. Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, Niho S, Nagai K and Saijo N: Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 62: 316-320, 2008.
11. Strobel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S and Marx A: Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350: 2625-2626, 2004. (Pubitemid 38758557)
12. Pan CC, Chen PC and Chiang H: KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 202: 375-381, 2004.
13. Masaoka A, Monden Y, Nakahara K and Tanioka T: Follow-up study of thymomas with special reference to their clinical stages. Cancer 48: 2485-2492, 1981. (Pubitemid 12228012)
14. Tatusova TA and Madden TL: BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences. FEMS Microbiol Lett 174: 247-250, 1999.
15. Hirota S, Isozaki K, Moriyama Y, K. Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad G, Matsuzawa Y, Kanakura Y, Shinomura Y and Kitamura Y: Gain-of-function mutations of C-KIT in human gastrointestinal stromal tumors. Science 279: 577-580, 1998. (Pubitemid 28067289)
16. Tsujimura T, Hashimoto K, Kitayama H, Ikeda H, Sugahara H, Matsumura I, Kaisho T, Terada N, Kitamura Y and Kanakura Y: Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Blood 15: 1319-1329, 1999. (Pubitemid 29076147)
17. Dibb NJ, Dilworth SM and Mol CD: Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Canc 4: 718-727, 2004.
18. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001.
19. Heldin CH, Ostman A and Ronnstrand L: Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1378: F79-F113, 1998. (Pubitemid 28381127)
20. Penzel R, Aulmann S, Moock M, Schwarzbach M, Rieker RJ and Mechtersheimer G: The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. J Clin Pathol 58: 634-639, 2005. (Pubitemid 40814026)
21. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD and Fletcher JA: PDGFRA-activating mutations in gastrointestinal stromal tumors. Science 299: 708-710, 2003. (Pubitemid 36159485)
22. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y and Kitamura Y: Gain-of-function mutations of platelet-derived growth factor receptor a gene in gastrointestinal stromal tumors. Gastroenterology 125: 660-667, 2003. (Pubitemid 37070684)
23. Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, Fuh G, Gerber HP and Ferrara N: VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23: 2800-2810, 2004. (Pubitemid 39013552)
24. Klinghoffer RA, Mueting-Nelsen PF, Faerman A, Shani M, and Soriano P: The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions. Mol Cell 2: 343-354, 2001. (Pubitemid 32206502)
25. Plattner R, Koleske AJ, Kazlauskas A and Pendergast AM: Bidirectional signaling links the Abelson kinases to the platelet derived growth factor receptor. Mol Cell Biol 24: 2573-2583, 2004. (Pubitemid 38326010)
26. Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, Gabanti E, Greco A, Casali PG, Carbone A, Pierotti MA and Pilotti S: PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol 208: 615-623, 2006.
27. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ and Bar-Eli M: Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8: 3584-3591, 2002. (Pubitemid 35340737)
28. Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, Tomlins SA, Chinnaiyan AM and Rubin MA: Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 6: 503-512, 2004. (Pubitemid 39411086)
29. Kim R, Emi M, Arihiro K, Tanabe K, Uccida Y and Toge T: Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 103: 1800-1809, 2005.